2 Information about enzalutamide
|
Marketing authorisation indication |
Enzalutamide (Xtandi, Astellas) has a marketing authorisation 'for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer'. |
|---|---|
|
Dosage in the marketing authorisation |
Enzalutamide is administered orally at a dose of 160 mg (4×40 mg soft capsules) daily. |
|
Price |
£2,734.67 per 112 capsules (excluding VAT; British national formulary online, accessed December 2018) The daily dose comprises 4 capsules and costs £97.67. The company has a commercial arrangement which would apply if the technology had been recommended. |